KR20240056751A - Sstr4 효능제 염 - Google Patents

Sstr4 효능제 염 Download PDF

Info

Publication number
KR20240056751A
KR20240056751A KR1020247011858A KR20247011858A KR20240056751A KR 20240056751 A KR20240056751 A KR 20240056751A KR 1020247011858 A KR1020247011858 A KR 1020247011858A KR 20247011858 A KR20247011858 A KR 20247011858A KR 20240056751 A KR20240056751 A KR 20240056751A
Authority
KR
South Korea
Prior art keywords
compound
formula
compound according
patient
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247011858A
Other languages
English (en)
Korean (ko)
Inventor
데이비드 앤드류 코티스
데이비드 마이클 레믹
Original Assignee
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 일라이 릴리 앤드 캄파니 filed Critical 일라이 릴리 앤드 캄파니
Publication of KR20240056751A publication Critical patent/KR20240056751A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/265—Citric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020247011858A 2021-09-14 2022-09-14 Sstr4 효능제 염 Pending KR20240056751A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163243785P 2021-09-14 2021-09-14
US63/243,785 2021-09-14
PCT/US2022/076401 WO2023044326A1 (en) 2021-09-14 2022-09-14 Sstr4 agonist salts

Publications (1)

Publication Number Publication Date
KR20240056751A true KR20240056751A (ko) 2024-04-30

Family

ID=83508479

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247011858A Pending KR20240056751A (ko) 2021-09-14 2022-09-14 Sstr4 효능제 염

Country Status (19)

Country Link
US (2) US11834435B2 (https=)
EP (1) EP4402136A1 (https=)
JP (2) JP2024533482A (https=)
KR (1) KR20240056751A (https=)
CN (1) CN117940413A (https=)
AR (1) AR127055A1 (https=)
AU (1) AU2022348561B2 (https=)
CA (1) CA3231451A1 (https=)
CL (2) CL2024000683A1 (https=)
CO (1) CO2024003038A2 (https=)
CR (1) CR20240118A (https=)
DO (1) DOP2024000050A (https=)
EC (1) ECSP24020256A (https=)
IL (1) IL311251A (https=)
JO (1) JOP20240053A1 (https=)
MX (1) MX2024003119A (https=)
PE (1) PE20240885A1 (https=)
TW (3) TWI860849B (https=)
WO (1) WO2023044326A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI860849B (zh) * 2021-09-14 2024-11-01 美商美國禮來大藥廠 Sstr4促效劑鹽
AU2024236692A1 (en) * 2023-03-10 2025-10-16 Eli Lilly And Company Methods for the preparation and dose regimens for use of sstr4 agonists and salts thereof
WO2025096300A1 (en) * 2023-10-30 2025-05-08 Eli Lilly And Company Novel methods for the preparation of 3-azabicylco[3.1,0]hexane-6-carboxamide derivatives
TW202600537A (zh) 2024-03-11 2026-01-01 美商美國禮來大藥廠 Ｓｓｔｒ４促效劑化合物及其組合物
GB202408483D0 (en) 2024-06-13 2024-07-31 Maxion Therapeutics Ltd Receptor agonists

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6159941A (en) 1996-05-14 2000-12-12 Novo Nordisk A/S Use of somatostatin agonists and antagonists for treating diseases related to the eye
US6355613B1 (en) 1996-07-31 2002-03-12 Peptor Limited Conformationally constrained backbone cyclized somatostatin analogs
US6063796A (en) 1997-04-04 2000-05-16 Merck & Co., Inc. Somatostatin agonists
US6057338A (en) 1997-04-04 2000-05-02 Merck & Co., Inc. Somatostatin agonists
EP1565436B1 (en) 2002-11-27 2012-04-25 Incyte Corporation 3-aminopyrrolidine derivatives as modulators of chemokine receptors
FI20031454A0 (fi) 2003-10-06 2003-10-06 Juvantia Pharma Ltd Oy Selektiivisiä somatostatiinireseptori 1 ja/tai 4 -agonisteja ja -antagonisteja
US20100004339A1 (en) 2003-10-06 2010-01-07 Oy Juvantia Pharma Ltd. Somatostatin Receptor 1 and/or 4 Selective Agonists and Antagonists
RS20060190A (sr) 2003-10-14 2008-08-07 Pfizer Products Inc., Biciklični /3.1.0/ derivati kao inhibitori transportera glicina
WO2007029086A2 (en) 2005-09-05 2007-03-15 Ranbaxy Laboratories Limited Derivatives of 3-azabicyclo[3.1.0]hexane as dipeptidyl peptidase-iv inhibitors
GB0616574D0 (en) 2006-08-21 2006-09-27 Glaxo Group Ltd Compounds
CA2672373C (en) 2006-12-19 2011-08-30 Pfizer Products Inc. Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
CA2729767A1 (en) 2008-07-07 2010-01-14 Fasgen, Inc. Novel compounds, pharmaceutical compositions containing same, methods of use for same, and methods for preparing same
WO2010059922A1 (en) 2008-11-21 2010-05-27 Ligand Pharmaceuticals Incorporated Pyrrolidine carboxamide compounds
US8835472B2 (en) 2010-09-02 2014-09-16 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical compositions and uses thereof
BR112013007566A2 (pt) 2010-09-28 2016-08-02 Panacea Biotec Ltd novos compostos bicíclicos
EP2685828A4 (en) 2011-03-17 2014-08-13 Merck Sharp & Dohme SUBSTITUTED 3-AZABICYCLO [3,1,0-] HEXAN DERIVATIVES AS CCR2 ANTAGONISTS
CN102675290B (zh) 2011-03-18 2014-11-12 山东亨利医药科技有限责任公司 含有并环的二氢吡唑类化合物
KR101556318B1 (ko) 2013-05-15 2015-10-01 한국과학기술연구원 칼슘이온 채널 조절제로서 유효한 6-피라졸일아미도-3-치환된 아자바이사이클로[3.1.0]헥산 유도체
US9371282B2 (en) * 2013-05-17 2016-06-21 Centrexion Therapeutics Corporation Somatostatin receptor subtype 4 (SSTR4) agonists
WO2016075239A1 (en) 2014-11-14 2016-05-19 Boehringer Ingelheim International Gmbh Aryl and heteroaryl-fused tetrahydro-1,4-oxazepine amides as somatostatin receptor subtype 4 (sstr4) agonists
BR112017009595A2 (pt) 2014-11-14 2017-12-19 Boehringer Ingelheim Int morfolina e 1,4-oxazepano amidas como agonistas do subtipo de receptor de somatostatina 4 (sstr4)
JP7774312B2 (ja) 2020-05-21 2025-11-21 クワンチョウ フェルミオン テクノロジー カンパニー リミテッド 縮合環化合物、それらの製造方法、医薬組成物、およびそれらの使用
WO2021233428A1 (zh) 2020-05-21 2021-11-25 广州费米子科技有限责任公司 含氮饱和杂环化合物及其制备方法、药物组合物和应用
WO2022012534A1 (zh) 2020-07-13 2022-01-20 广州费米子科技有限责任公司 含氮杂环化合物、药物组合物和应用
TWI860849B (zh) * 2021-09-14 2024-11-01 美商美國禮來大藥廠 Sstr4促效劑鹽

Also Published As

Publication number Publication date
CN117940413A (zh) 2024-04-26
MX2024003119A (es) 2024-04-09
ECSP24020256A (es) 2024-04-30
TWI860849B (zh) 2024-11-01
TWI822326B (zh) 2023-11-11
TW202400577A (zh) 2024-01-01
JP2024533482A (ja) 2024-09-12
AU2022348561B2 (en) 2025-05-22
IL311251A (en) 2024-05-01
US12486249B2 (en) 2025-12-02
AR127055A1 (es) 2023-12-13
EP4402136A1 (en) 2024-07-24
JP2025111617A (ja) 2025-07-30
CA3231451A1 (en) 2023-03-23
TW202444703A (zh) 2024-11-16
CR20240118A (es) 2024-04-25
CO2024003038A2 (es) 2024-04-18
TW202330492A (zh) 2023-08-01
CL2025002158A1 (es) 2025-11-07
WO2023044326A1 (en) 2023-03-23
PE20240885A1 (es) 2024-04-24
US11834435B2 (en) 2023-12-05
JOP20240053A1 (ar) 2024-03-12
CL2024000683A1 (es) 2024-08-23
DOP2024000050A (es) 2024-04-30
AU2022348561A1 (en) 2024-03-14
US20230099116A1 (en) 2023-03-30
US20240067628A1 (en) 2024-02-29

Similar Documents

Publication Publication Date Title
US12486249B2 (en) SSTR4 agonist salts
EP4025572B1 (en) Heterocyclic rip1 kinase inhibitors
EP3788045B1 (en) Rip1 inhibitory compounds and methods for making and using the same
JP5022909B2 (ja) ２，４（４，６）ピリミジン誘導体
CN108395443B (zh) 抑制程序性死亡受体配体1的环状化合物及其用途
US20180282310A1 (en) Forms and compositions of biaryl inhibitors of bruton's tyrosine kinase
WO2023124824A1 (zh) 一种glp-1激动剂的盐及其晶型和在医药上的应用
CN111132984A (zh) 凋亡信号调节激酶1抑制剂的盐及其晶型
CN110603256A (zh) 可用作wee-1激酶抑制剂的嘧啶并嘧啶酮
CN113906020B (zh) 环状缓激肽b2受体拮抗剂
CN117642416A (zh) 分拣蛋白活性调节剂
JP2023525951A (ja) グルタルイミド骨格に基づく化合物及びその使用
WO2021100019A1 (en) Prodrugs of abiraterone
CN110872277A (zh) N-取代芳环-2-氨基嘧啶类化合物及用途
JP2020073523A (ja) 置換されたイミダゾピリジニル−アミノピリジン化合物の塩および多型
EA050624B1 (ru) Соли агониста sstr4
JP2023543080A (ja) ピロロ複素環系誘導体の結晶及びその製造方法
WO2024026262A1 (en) Substituted pyrazolyl-pyridinyl compounds as ligand directed degraders of irak3
US20250320215A1 (en) Salts of n-[4-(4-[[2-(dimethylamino)ethyl]amino]-3-methyl-1h-pyrazolo[3,4-d]pyrimidin-6-yl)-2-fluorophenyl]-2,5-difluorobenzenesulfonamide and crystalline forms thereof
WO2024213088A1 (zh) 嘧啶三并环衍生物的结晶及用途
EP4703363A1 (en) Salt form and crystal form of thienopyrimidine compound, and preparation method therefor and use thereof
CN115490640A (zh) 取代的苯并咪唑类化合物及包含该化合物的组合物及其用途
TW202110429A (zh) 環狀緩激肽b2受體拮抗劑
AU2005306048A1 (en) Agonists and antagonists of the somatostatin receptor

Legal Events

Date Code Title Description
A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902